Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection.

Antiviral therapy - 1 Feb 2024

Boussen Inès, Salmona Maud, Sicre De Fontbrune Flore, Xhaard Aliénor, De Castro Nathalie, Delaugerre Constance, Chaix Marie-Laure, Molina Jean-Michel

Abstract excerpt

We report the case of an allogeneic stem cell transplant recipient with nosocomial acquisition of SARS-CoV-2 infection who received antispike neutralizing monoclonal antibody bamlanivimab 2 days after diagnosis of SARS-CoV-2 infection but progressed to severe COVID-19 pneumonia and died with the selection of E484K/Q resistance mutations to bamlanivimab.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19

Share to Cross Infection

Share to Hematopoietic Stem Cell Transplantation

Share to Mutation

Share to SARS-CoV-2

Share to Stem Cell Transplantation

Source

Identifiers

PMID: 38353416
DOI: 10.1177/13596535221097495

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection.PMID 38353416Read ↗

Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2.Semantic proximity Read ↗

Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in GermanySemantic proximity Read ↗

Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed PatientSemantic proximity Read ↗

Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In VitroSemantic proximity Read ↗

Pre-exposure prophylaxis for COVID-19 with Tix-agevimab/Cilgavimab in kidney transplant recipients in the Kraken variant (XBB.1.5) era: A Single-center ExperienceSemantic proximity Read ↗

Breakthrough Covid-19 cases despite tixagevimab and cilgavimab (Evusheld™) prophylaxis in kidney transplant recipientsSemantic proximity Read ↗

Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipientsSemantic proximity Read ↗

Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19.Semantic proximity Read ↗

Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 daysSemantic proximity Read ↗

Next generation treatment of acute graft-versus-host diseaseSemantic proximity Read ↗

SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantationSemantic proximity Read ↗

Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.